Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square
|
June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
The Lancet. Haematology
|
December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study
Michael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy
|
April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations
Moataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Leukemia & Lymphoma
|
April 2, 2020
The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients
Richard J Lin, Laure Michaud, Stephanie M Lobaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Ross S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Hematology & Oncology
|
April 22, 2024
Conventional and novel [<sup>18</sup>F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
Doris Leithner, Jessica R Flynn, Sean M Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
Roni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Blood Advances
|
December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults
Juliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square
|
June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
The Lancet. Haematology
|
December 3, 2025
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study
Michael Scordo, Miguel-Angel Perales, Audrey Mauguen, et al.
Transplantation and Cellular Therapy
|
April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations
Moataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Leukemia & Lymphoma
|
April 2, 2020
The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients
Richard J Lin, Laure Michaud, Stephanie M Lobaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Ross S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Hematology & Oncology
|
April 22, 2024
Conventional and novel [<sup>18</sup>F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
Doris Leithner, Jessica R Flynn, Sean M Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
Roni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Blood Advances
|
December 8, 2020
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults
Juliet N Barker, Sean M Devlin, Kristine A Naputo, et al.
Page
of 13